M
美加康
HEALTH8/21/2026

Is Stem Cell Therapy Safe? Experts Explain Indications and Risks

Stem cell therapy is a hot topic in healthcare, but its safety and efficacy are often confused. Based on international clinical guidelines, this article analyzes the true indications of stem cell therapy (such as blood system diseases, autoimmune diseases, etc.), potential risks (such as tumorigenicity, immune rejection), and the current regulatory landscape, providing practical advice for patients to choose legitimate institutions and avoid pitfalls.

Introduction

"One injection of stem cells, rejuvenation" "Repair damaged organs, cure chronic diseases"—these slogans make stem cell therapy sound like a miracle cure-all. However, in the medical community, stem cell therapy remains under strict regulation, and its safety and efficacy vary from person to person. As a cross-border medical platform, we often receive patient inquiries: "Is stem cell therapy safe?" Today, we will break down the indications, risks, and selection points of stem cells from scientific and regulatory perspectives to help you make rational decisions.

What Is Stem Cell Therapy? Indications Are Much Narrower Than Imagined

Stem cells are a class of cells with self-renewal and multi-lineage differentiation potential, theoretically capable of repairing damaged tissues. However, clinical application is not "universal." Currently, globally recognized and mature stem cell therapies are mainly limited to hematopoietic stem cell transplantation (e.g., bone marrow transplantation) for treating malignant blood diseases such as leukemia, lymphoma, and multiple myeloma. Additionally, mesenchymal stem cell (MSC) clinical trials in autoimmune diseases (e.g., Crohn's disease, systemic lupus erythematosus), osteoarthritis, and diabetic foot ulcers have shown positive results, but most remain in the research stage and are not yet widespread.

According to the International Society for Stem Cell Research (ISSCR) guidelines, stem cell therapy requires clear indications and must undergo rigorous clinical trial validation. For example, the U.S. FDA has approved only a few cell therapies, such as CAR-T therapy for pediatric acute lymphoblastic leukemia (which involves genetically modified immune cells) and the MACI technique for repairing cartilage damage. In China, the National Health Commission and the Drug Administration also issued the "Measures for the Management of Stem Cell Clinical Research" in 2023, requiring that stem cell clinical research be conducted in tertiary Grade A hospitals and that no fees be charged to patients. Therefore, when you hear about "cure-all" stem cell packages, be cautious.

Risks: Not "Zero Risk," Three Major Hazards to Watch

Stem cell therapy is not absolutely safe, and its risks mainly come from three aspects:

  • Tumorigenicity: After in vitro expansion or in vivo transplantation, stem cells carry a risk of abnormal differentiation and tumor formation. Especially embryonic stem cells or induced pluripotent stem cells (iPSCs), if not controlled, may form teratomas. Although mesenchymal stem cells have a lower tumorigenic risk, long-term safety data remain insufficient.
  • Immune Rejection: After allogeneic stem cell transplantation, host immune rejection may occur, manifesting as fever, rash, and liver or kidney dysfunction. Although autologous stem cells carry no such risk, the collection and reinfusion process may also lead to infection or embolism.
  • Complications from Improper Procedures: If medical institutions lack qualifications, the stem cell preparation process may be contaminated, or improper injection sites may cause local infection, nerve damage, etc. In 2021, the U.S. FDA warned of multiple incidents where unapproved stem cell products caused patient blindness and infections.
  • Therefore, when assessing safety, be sure to focus on clinical data, institutional qualifications, and operational procedures, rather than just listening to promotional claims.

    How to Distinguish Legitimate from Illegal? Key Points to Check

    When choosing stem cell therapy, evaluate from the following three aspects:

  • Institutional Qualifications: Legitimate institutions should have clinical research filings with the National Health Commission or Drug Administration, or hold international certifications such as FDA. You can view the certification information of partner hospitals on our MegaCare Services Page.
  • Treatment Indications: Legitimate institutions will strictly screen patients and clearly inform the purpose of treatment (e.g., for clinical trials rather than commercial promotion). If someone claims to treat all diseases without any examinations, refuse immediately.
  • Transparent Costs: Legal stem cell clinical research is usually free or only charges for cell preparation costs. If you are asked to prepay tens of thousands of yuan in "treatment fees" without contractual guarantees, be cautious. We provide a cost estimator to help you estimate cross-border medical expenses.
  • International Regulation and Cross-Border Medical Considerations

    Laws regarding stem cell therapy vary significantly across countries: Japan allows commercial use under specific conditions but requires follow-up; the U.S. FDA treats it as a drug requiring approval; the EU imposes strict restrictions. If you are considering cross-border treatment, pay attention to the regulatory policies of the destination country and retain medical records. For example, Japan's "Act on the Safety of Regenerative Medicine" implemented in 2014 requires submission of efficacy data for stem cell therapy, but there is still controversy in clinical practice. Therefore, it is recommended to choose internationally accredited hospitals and consult our medical advisors for case-by-case evaluation.

    Recommendations for International Patients

    Stem cell therapy is neither a "scourge" nor a "miracle drug." We recommend:

  • Clarify Diagnosis: First, get a confirmed diagnosis at a legitimate hospital to determine whether your disease falls within the indications for stem cell therapy.
  • Review Evidence: Search for clinical trial results for that indication (e.g., on ClinicalTrials.gov), focusing on sample size and long-term follow-up.
  • Consult Experts: Use MegaCare to schedule remote consultations with authoritative domestic and international experts for a second opinion.
  • Assess Risk-Benefit Ratio: If your disease is in its early stages, prioritize conventional treatment; if conventional treatment fails, then consider stem cell research programs.
  • Finally, remember: safety comes from science, not miracles. If you have specific questions, feel free to contact us, and we will provide objective medical information to help you make informed choices.

    Disclaimer: This article is for informational purposes only. Individual outcomes vary. Always consult with qualified medical professionals before making treatment decisions. Contact MedBridge Shanghai for personalized consultation.

    Ready to Start Your Medical Journey?

    Free consultation with our medical experts. Get a personalized treatment plan within 48 hours.

    Free Consultation